Literature DB >> 35770383

Letter to the Editor re: "Refractive and Vision Status in Down Syndrome: A Comparative Study".

Pathum Sookaromdee1, Viroj Wiwanitkit2.   

Abstract

Entities:  

Keywords:  Down syndrome; refractive; vision

Mesh:

Year:  2022        PMID: 35770383      PMCID: PMC9249108          DOI: 10.4274/tjo.galenos.2022.53484

Source DB:  PubMed          Journal:  Turk J Ophthalmol        ISSN: 2149-8709


× No keyword cloud information.
Dear editor, We would like to share our ideas on the publication “Refractive and Vision Status in Down Syndrome: A Comparative Study.”[1] Hashemi et al.[1] concluded that “In DS patients, the prevalence rates of refractive errors, amblyopia, and visual impairment are higher than those in non-DS individuals.” Regarding DS and refractive/vision problems, there should be a hypothesis for the clinical association. How DS might contribute to ocular problems should be proposed. In a recent report, the possible mechanism was cerebral visual impairment, not an intraocular problem.[2] This might not be concluded based on the findings of the present study. An important concern is about the control group. The control group is only a group of non-DS cases but not healthy controls. For example, “candidates for refractive surgery” must have an ocular problem. Additionally, Hashemi et al.[1] mentioned “age- and gender-matched normal controls,” but there were unequal numbers of subjects in the patient and control groups. Hence, there might be a methodological flaw and bias.
  2 in total

1.  Refractive and Vision Status in Down Syndrome: A Comparative Study

Authors:  Hassan Hashemi; Shiva Mehravaran; Soheila Asgari; Farzaneh Dehghanian Nasrabadi
Journal:  Turk J Ophthalmol       Date:  2021-08-27

2.  Behavioural Features of Cerebral Visual Impairment Are Common in Children With Down Syndrome.

Authors:  Gemma J Wilton; Rhodri Woodhouse; Valldeflors Vinuela-Navarro; Rachel England; J Margaret Woodhouse
Journal:  Front Hum Neurosci       Date:  2021-06-14       Impact factor: 3.169

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.